Targeted (nano)therapeutics/(nano)theranostics for diagnosis and treatment of liver diseases
Myofibroblasts and macrophages are the key cell types that are involved in the initiation and progression of liver diseases, We have made dedicated efforts towards the development of targeted therapies focusing on these two major cell types. Myofibroblasts-specific (nano)therapeutics or (nano)theranostics for the diagnosis and treatment of liver diseases: We have made significant contributions in the development of HSCs-specific (nano)targeting strategies to deliver drugs specifically to HSCs thereby improving the therapeutic efficacy of drugs and eliminating the off-target adverse effects in other cells and tissues. The recent advancement of theranostics (therapy and diagnostics) have opened a new horizon in this field. Innovative nanotheranostics provide personalized platforms by diagnosing the fibrosis stage, applying a tailored treatment based on diagnosis and finally monitoring the treatment effects. Macrophages-specific (nano)therapeutics or (nano) theranostics for the diagnosis and treatment of liver diseases: We have been actively working on the development of unique macrophage-specific (nano)therapies for the selective inhibition of liver inflammation. These innovative nanoplatforms are like nanorobots that can track the site of injury, and deliver required drugs without affecting neighbouring organs and cells.